GlassScriptPhysician profile
Joseph Ferrara
NPI 1215925979
$3,794.06
in general payments reported to CMS, 2019-2025
35 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $271 · 2021: $502 · 2022: $596 · 2023: $944 · 2024: $637 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $399.24 | 2019-2025 | |
| Amgen INC. | $372.62 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $289.14 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $277.38 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $200.47 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Daiichi Sankyo INC. | $169.66 | 2021-2025 | Injectafer |
| Abbott Laboratories | $140.39 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $135.89 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.91 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $78.92 | 2021-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Esperion Therapeutics, INC. | $69.79 | 2021-2024 | Nexletol |
| Vbi Vaccine (Delaware) INC. | $66.49 | 2022-2023 | Prehevbrio |
| Alexion Pharmaceuticals, INC. | $64.95 | 2022-2024 | Ultomiris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.46 | 2019-2025 | |
| Astellas Pharma US INC | $47.60 | 2022-2025 | Veozah |
| Lundbeck LLC | $46.39 | 2022-2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $37.12 | 2021 | |
| Philips North America LLC | $36.67 | 2023 | |
| Allergan, INC. | $35.18 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.30 | 2022 | |
| Edwards Lifesciences Corporation | $31.05 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2021-2024 | Eliquis |
| Inspire Medical Systems, INC. | $24.77 | 2024 | Inspire |
| Corcept Therapeutics | $21.42 | 2023 | Korlym |
| Bausch Health US, LLC | $20.75 | 2025 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.88 | 2025 | Xifaxan |
| Harmony Biosciences LLC | $18.92 | 2020 | |
| Hologic Sales and Service, LLC | $18.26 | 2023 | Aptima |
| Teva Pharmaceuticals USA, INC. | $16.27 | 2020 | |
| Linus Health, INC. | $16.17 | 2023 | |
| Sanofi Pasteur INC. | $15.18 | 2019 | |
| Amarin Pharma, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ferrara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.